TITLE

The Effect of Therapeutic Plasma Exchange on the Bioavailability of Interferon Beta. Pilot Study

AUTHOR(S)
Giedraitiene, N.; Kizlaitiene, R.; Budrys, V.; Kaubrys, G.; Griskevicius, L.; Valceckiene, V.; Stoskus, M.; Griskevicius, A.; Audzijoniene, J.
PUB. DATE
December 2013
SOURCE
Neurologijos Seminarai;2013, Vol. 17 Issue 4, p288
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Back ground and purpose. The development of neutralizing antibodies (NAbs) against interferon beta (IFN-β) during IFN-β treatment in multiple sclerosis (MS) patients has been a significant clinical problem. Persistent, high-titer NAbs-IFN-β reduce or eliminate biological activity of IFN-β therapies for MS and are associated with reduction in efficacy. Therapeutic plasma exchange (TPE) removes the circulating antibodies that are thought to be active in the diseases, so we hypothesized that TPE can restore the ability of IFN-β to induce the Myxovirus Resistance Protein A (MxA) mRNA expression and the maintenance plasmapheresis can sustain the bioavailability of IFN-β. Methods. Eligible patients under went primarily four separate plasma exchange sessions and after the induction TPE sessions they were transferred to the maintenance plasma pheresis. Bioactivity of interferon beta was expressed as in vivo MxA mRNA induction in whole blood using real time PCR. Results. Six patients with RRMS and low IFN-β bioavailability detected by the MxA mRNA response were included. Four patients after induction plasmapheresis be came biological responders. In two patients an in crease of MxA mRNA expression was found, but the values persisted be low the cut-off and the patients remained as "poor biological responders". The effect of maintenance plasmapheresis was quite transient: MxA mRNA expression values reverted to the base line levels after one or two months. Conclusion. Plasma exchange may restore the bioavailability of IFN-β in some patients, but the effect of maintenance plasmapheresis on the bioavailability of IFN-β is transient.
ACCESSION #
44189387

 

Related Articles

  • The Effect of Therapeutic Plasma Exchange on the Bioavailability of Interferon Beta. Pilot Study. Giedraitiene, N.; Kizlaitiene, R.; Budrys, V.; Kaubrys, G.; Griskevicius, L.; Valceckiene, V.; Stoskus, M.; Griskevicius, A.; Audzijoniene, J. // Neurologijos Seminarai;2013, Vol. 17 Issue 4, p288 

    Back ground and purpose. The development of neutralizing antibodies (NAbs) against interferon beta (IFN-β) during IFN-β treatment in multiple sclerosis (MS) patients has been a significant clinical problem. Persistent, high-titer NAbs-IFN-β reduce or eliminate biological activity of...

  • INTERFERONS, BETA.  // Davis's Drug Guide for Nurses, 9th edition;2005, p556 

    Provides information on interferons, beta, an anti-multiple sclerosis agent. Indications; Therapeutic effects; Pharmacokinetics; Contraindications and precautions; Side effects.

  • Anti-viral properties of interÆ’eron beta treatment in patients with multiple sclerosis. Hong, J.; Tejada-Simon, M.V.; Rivera, V.M.; Zang, Y.C.Q.; Zhang, J.Z. // Multiple Sclerosis (13524585);May2002, Vol. 8 Issue 3, p237 

    Focuses on a study which evaluated the in-vivo anti-viral effects of interferon beta (IFN beta) 1a in patients with multiple sclerosis. Background of the study population; Therapeutic use of IFN beta; Detection of cell-free human herpesvirus-6 (HHV-6) DNA; Effects of IFN beta on viral...

  • Population based cost utility study of interferon beta-lb in secondary progressive multiple... Forbes, Raeburn B.; Lees, Ann // BMJ: British Medical Journal (International Edition);12/11/99, Vol. 319 Issue 7224, p1529 

    Presents a study which evaluated the cost utility of interferon beta-1b in secondary progressive multiple sclerosis. Comparison of the effect of treating people with secondary progressive multiple sclerosis with interferon beta against practice without interferon beta; Results of the study;...

  • Does fingolimod transform MS treatment?  // PharmacoEconomics & Outcomes News;7/21/2012, Issue 658, p3 

    The article discusses research on the cost effectiveness of early initiation of fingolimod compared with delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis, referencing a study by N. Agashivala et al published in the June 27, 2012 issue of...

  • Early interferon-β-1b dominates in MS.  // PharmacoEconomics & Outcomes News;5/26/2012, Issue 654, p6 

    The article discusses research on the cost-effectiveness of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis, referencing a study by J. P. Caloyeras and colleagues published on the April 26, 2012 issue of "Clinical Therapeutics."

  • Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients. Garcia-Montojo, Marta; Heras, Virginia De Las; Bartolome, Manuel; Arroyo, Rafael; Alvarez-Lafuente, Roberto // Journal of NeuroVirology;Dec2007, Vol. 13 Issue 6, p504 

    Viral infections have been appointed as the main component of environmental susceptibility to multiple sclerosis (MS). Interferon beta is an immunomudulatory treatment that is able to modify the natural course of the disease; nonetheless, its mechanism of action in not well established yet. The...

  • Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study. Jacques, F.; Gaboury, I.; Christie, S.; Maison, F. Grand // Multiple Sclerosis International;2012, p1 

    Tacrolimus is a calcineurin inhibitor which works to induce immune suppression by preventing cytokine transcription and lymphocyte activation. Combining the immunomodulator interferon beta-1b (Betaseron) with the immunosuppressant tacrolimus (Prograf) may have the potential of additive...

  • Skuteczność różnych preparatów interferonu beta w stwardnieniu rozsianym. PrzeglÄ…d otwartych badaÅ„ porównawczych. Berkowicz, Tomasz // Neuropsychiatry & Neuropsychology / Neuropsychiatria i Neuropsyc;2012, Vol. 7 Issue 4, p175 

    Beta interferon is the first-line immunomodulatory agent approved for remitting-relapsing multiple sclerosis. Several preparations of interferon beta 1b and interferon beta 1a are available for treatment. The author reviews the publications on 13 open-label studies comparing the efficacy of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics